Cefuroxime
Identification
- Summary
Cefuroxime is a cephalosporin indicated for the treatment of a variety of infections including acute bacterial otitis media, several upper respiratory tract infections, skin infections, urinary tract infections, gonorrhea, early Lyme disease, and impetigo.
- Brand Names
- Ceftin
- Generic Name
- Cefuroxime
- DrugBank Accession Number
- DB01112
- Background
Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
- Average: 424.385
Monoisotopic: 424.068884198 - Chemical Formula
- C16H16N4O8S
- Synonyms
- (6R,7R)-3-[(carbamoyloxy)methyl]-7-{[(2Z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- Cefuroxim
- Cefuroxima
- Cefuroxime
- Cefuroximo
- Cefuroximum
- Cephuroxime
Pharmacology
- Indication
For the treatment of many different types of bacterial infections such as bronchitis, sinusitis, tonsillitis, ear infections, skin infections, gonorrhea, and urinary tract infections.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Acute bacterial exacerbation of chronic bronchitis •••••••••••• •••••• Used in combination to treat Animal bite ••• ••••• Prophylaxis of Bacterial infection •••••••••••• Treatment of Bacterial infections •••••••••••• Treatment of Bone and joint infections •••••••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Cefuroxime is a β-lactam type antibiotic. More specifically, it is a second-generation cephalosporin. Cephalosporins work the same way as penicillins: they interfere with the peptidoglycan synthesis of the bacterial wall by inhibiting the final transpeptidation needed for the cross-links. This effect is bactericidal. Cefuroxime is effective against the following organisms: Aerobic Gram-positive Microorganisms: Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes. Aerobic Gram-negative Microorganisms: Escherichia coli, Haemophilus influenzae (including beta-lactamase-producing strains), Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis (including beta-lactamase-producing strains), Neisseria gonorrhoeae (including beta-lactamase-producing strains). Spirochetes: Borrelia burgdorferi. Cefuroxime axetil is the prodrug
- Mechanism of action
Cefuroxime, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefuroxime interferes with an autolysin inhibitor.
Target Actions Organism APenicillin-binding protein 1A inhibitorClostridium perfringens (strain 13 / Type A) - Absorption
Absorbed from the gastrointestinal tract. Absorption is greater when taken after food (absolute bioavailability increases from 37% to 52%).
- Volume of distribution
Not Available
- Protein binding
50% to serum protein
- Metabolism
The axetil moiety is metabolized to acetaldehyde and acetic acid.
Hover over products below to view reaction partners
- Route of elimination
Not Available
- Half-life
Approximately 80 minutes following intramuscular or intravenous injection.
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Allergic reactions might be expected, including rash, nasal congestion, cough, dry throat, eye irritation, or anaphylactic shock. Overdosage of cephalosporins can cause cerebral irritation leading to convulsions.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Cefuroxime may decrease the excretion rate of Abacavir which could result in a higher serum level. Abciximab The therapeutic efficacy of Abciximab can be decreased when used in combination with Cefuroxime. Aceclofenac The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Aceclofenac. Acemetacin The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding can be increased when Cefuroxime is combined with Acenocoumarol. - Food Interactions
- Take with food. Food increases absorption.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Cefuroxime axetil Z49QDT0J8Z 64544-07-6 KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime sodium R8A7M9MY61 56238-63-2 URDOHUPGIOGTKV-JTBFTWTJSA-M - Product Images
- International/Other Brands
- Cefurax (Lindopharm) / Elobact (GlaxoSmithKline) / Oraxim (Malesci) / Sharox (Fahrenheit) / Supacef (GlaxoSmithKline) / Zinacef danmark / Zinnat (GlaxoSmithKline)
- Brand Name Prescription Products
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Apo-cefuroxime Tablet 500 mg Oral Apotex Corporation 2001-08-29 Not applicable Canada Apo-cefuroxime Tablet 250 mg Oral Apotex Corporation 2001-08-29 Not applicable Canada Auro-cefuroxime Tablet 500 mg Oral Auro Pharma Inc 2012-01-13 Not applicable Canada Auro-cefuroxime Tablet 250 mg Oral Auro Pharma Inc 2012-01-13 Not applicable Canada Cefuroxime Injection, powder, for solution 7.5 g/80mL Intravenous Fresenius Kabi USA, LLC 2010-07-30 2013-02-18 US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image BIGCEF 250/125 MG FILM KAPLI TABLET, 10 ADET Cefuroxime axetil (250 mg) + Clavulanic acid (125 mg) Tablet, coated NEUTEC İLAÇ SAN. TİC. A.Ş. 2012-12-26 Not applicable Turkey BIGCEF 250/125 MG FILM KAPLI TABLET, 14 ADET Cefuroxime axetil (250 mg) + Clavulanic acid (125 mg) Tablet, coated NEUTEC İLAÇ SAN. TİC. A.Ş. 2012-12-26 Not applicable Turkey BIGCEF 250/125 MG FILM KAPLI TABLET, 20 ADET Cefuroxime axetil (250 mg) + Clavulanic acid (125 mg) Tablet, coated NEUTEC İLAÇ SAN. TİC. A.Ş. 2012-12-26 Not applicable Turkey BIGCEF 500/125 MG FILM KAPLI TABLET, 10 ADET Cefuroxime axetil (500 mg) + Clavulanic acid (125 mg) Tablet, coated NEUTEC İLAÇ SAN. TİC. A.Ş. 2012-12-26 Not applicable Turkey BIGCEF 500/125 MG FILM KAPLI TABLET, 14 ADET Cefuroxime axetil (500 mg) + Clavulanic acid (125 mg) Tablet, coated NEUTEC İLAÇ SAN. TİC. A.Ş. 2012-12-26 Not applicable Turkey
Categories
- ATC Codes
- S01AA27 — CefuroximeJ01DC02 — Cefuroxime
- J01DC — Second-generation cephalosporins
- J01D — OTHER BETA-LACTAM ANTIBACTERIALS
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as cephalosporin 3'-carbamates. These are cephalosporins that are substituted at the 3'-position by a carbamate group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Lactams
- Sub Class
- Beta lactams
- Direct Parent
- Cephalosporin 3'-carbamates
- Alternative Parents
- N-acyl-alpha amino acids and derivatives / 1,3-thiazines / Tertiary carboxylic acid amides / Carbamate esters / Furans / Heteroaromatic compounds / Secondary carboxylic acid amides / Azetidines / Organic carbonic acids and derivatives / Thiohemiaminal derivatives show 10 more
- Substituents
- Alpha-amino acid or derivatives / Aromatic heteropolycyclic compound / Azacycle / Azetidine / Carbamic acid ester / Carbonic acid derivative / Carbonyl group / Carboxamide group / Carboxylic acid / Carboxylic acid derivative show 19 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- oxime O-ether, furans, 3-(carbamoyloxymethyl)cephalosporin (CHEBI:3515)
- Affected organisms
- Enteric bacteria and other eubacteria
Chemical Identifiers
- UNII
- O1R9FJ93ED
- CAS number
- 55268-75-2
- InChI Key
- JFPVXVDWJQMJEE-IZRZKJBUSA-N
- InChI
- InChI=1S/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/b19-9-/t10-,14-/m1/s1
- IUPAC Name
- (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- SMILES
- [H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CC=CO1)C(O)=O
References
- Synthesis Reference
Vijay Kumar Handa, Ramesh Dandala, Jag Mohan Khanna, "Process for the preparation of cefuroxime." U.S. Patent US6235896, issued February, 1976.
US6235896- General References
- Perry CM, Brogden RN: Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1996 Jul;52(1):125-58. [Article]
- External Links
- Human Metabolome Database
- HMDB0015244
- KEGG Drug
- D00262
- KEGG Compound
- C06894
- PubChem Compound
- 5479529
- PubChem Substance
- 46506681
- ChemSpider
- 4586393
- BindingDB
- 50422689
- 2194
- ChEBI
- 3515
- ChEMBL
- CHEMBL1436
- ZINC
- ZINC000003871978
- Therapeutic Targets Database
- DAP000445
- PharmGKB
- PA448868
- PDBe Ligand
- KOV
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Cefuroxime
- PDB Entries
- 4kov
- FDA label
- Download (809 KB)
- MSDS
- Download (52.7 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Health Services Research Antibiotic Resistant Infection / Uncomplicated Urinary Tract Infections 1 4 Completed Prevention Infection 1 4 Completed Prevention Infection Prophylaxis in Colo Rectal Surgery 1 4 Completed Prevention Obesity; Drug 1 4 Completed Prevention Postoperative Infections 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Aidarex Pharmacuticals LLC
- Amerisource Health Services Corp.
- Apotex Inc.
- APP Pharmaceuticals
- A-S Medication Solutions LLC
- Aurobindo Pharma Ltd.
- B. Braun Melsungen AG
- Baxter International Inc.
- BMH Ltd.
- Bristol-Myers Squibb Co.
- Bryant Ranch Prepack
- Cardinal Health
- Cura Pharmaceutical Co. Inc.
- DAVA Pharmaceuticals
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Dorx LLC
- Elan Pharmaceuticals Inc.
- Eli Lilly & Co.
- F Hoffmann-La Roche Ltd.
- Forum Products Inc.
- GC Hanford Manufacturing Co.
- GlaxoSmithKline Inc.
- Greenstone LLC
- Hikma Pharmaceuticals
- Hospira Inc.
- Liberty Pharmaceuticals
- Lupin Pharmaceuticals Inc.
- Major Pharmaceuticals
- Murfreesboro Pharmaceutical Nursing Supply
- Northstar Rx LLC
- Nucare Pharmaceuticals Inc.
- Orchid Healthcare
- PD-Rx Pharmaceuticals Inc.
- Pharmaceutical Utilization Management Program VA Inc.
- Pharmedix
- Physicians Total Care Inc.
- Preferred Pharmaceuticals Inc.
- Prepak Systems Inc.
- Prescript Pharmaceuticals
- Ranbaxy Laboratories
- Rebel Distributors Corp.
- Resource Optimization and Innovation LLC
- Sagent Pharmaceuticals
- Samson Medical Technologies
- Sandhills Packaging Inc.
- Southwood Pharmaceuticals
- Stat Rx Usa
- Teva Pharmaceutical Industries Ltd.
- UDL Laboratories
- Watson Pharmaceuticals
- West-Ward Pharmaceuticals
- Wockhardt Ltd.
- World Gen LLC
- Zyber Pharmaceuticals
- Dosage Forms
Form Route Strength Injection Intramuscular; Intravenous 250 mg Injection, powder, for solution Intramuscular 750 mg Injection, powder, for solution Tablet, film coated Oral Injection, powder, for solution Intraocular 50 MG Injection, powder, for solution Parenteral 50 mg Injection Intraocular 50 mg Suspension Oral Capsule Oral Tablet, coated Injection Intramuscular Tablet Oral 500.000 mg Suspension Oral 2.500 g Tablet Oral 250.000 mg Injection, solution Intramuscular 250 mg Injection Intramuscular 500 mg Injection Intramuscular 750 mg Injection, powder, for solution Intravenous 1.5 gr Injection Intramuscular; Intravenous 0.75 G Granule, for suspension Oral 125 mg / 5 mL Powder, for suspension Oral 125 mg/5mL Powder, for suspension Oral 250 mg/5mL Powder Oral 250 mg / pck Powder, for solution Oral 250 mg / pck Powder, for solution Oral 125 mg / 5 mL Tablet Oral 250 mg / tab Tablet Oral 500 mg / tab Injection Intravenous Injection, solution Intramuscular 750 mg Injection, solution Intramuscular; Intravenous Granule Oral 125 MG/5ML Injection, powder, for suspension Intramuscular Injection Intramuscular; Intravenous 1.5 gr Injection Intramuscular 250 mg Injection, powder, for solution Parenteral 250 mg Injection, powder, for solution Parenteral Injection, powder, for solution Parenteral 1500 mg Injection, powder, for solution Parenteral 750 mg Injection, powder, for solution 1500 mg Solution Parenteral Injection, powder, for suspension Intramuscular 1 G/4ML Injection, powder, for suspension Intramuscular 500 MG/2ML Tablet Oral Injection, powder, for solution 50 MG Injection, powder, for solution Intramuscular; Intravenous; Parenteral 1.5 G Injection, powder, for solution Intramuscular; Intravenous; Parenteral 750 MG Injection, powder, for suspension Intramuscular 750 MG/3ML Tablet, coated Oral 125 MG Injection, powder, for solution Intramuscular; Intravenous 750 mg/1 Injection, powder, for solution Intravenous 1.5 g/1 Injection, powder, for solution Intravenous 1.5 g/100mL Injection, powder, for solution Intravenous 1.5 g/16mL Injection, powder, for solution Intravenous 7.5 g/1 Injection, powder, for solution Intravenous 7.5 g/80mL Injection, powder, for solution Intravenous 7.5 g/82.5mL Injection, powder, for solution Intravenous 750 mg/8mL Injection, powder, for solution Intravenous 750 mg/100mL Injection, powder, for solution Intravenous 95 mg/1mL Injection 750 mg Tablet, coated Oral 250 mg Tablet, coated Oral 500 mg Tablet Oral 125 mg/1 Tablet Oral 250 mg/1 Tablet Oral 500 mg/1 Tablet, film coated Oral 125 mg/1 Tablet, film coated Oral 250 mg/1 Tablet, film coated Oral 500 mg/1 Suspension Oral 125 mg/5mL Suspension Oral 250 mg/1mL Powder, for solution Intravenous 750 mg / vial Injection, powder, for solution Intravenous 225 g/1 Injection, powder, for solution Intravenous 75 g/1 Injection, powder, for solution Intramuscular; Intravenous 250 mg Injection, powder, for solution Intramuscular; Intravenous Injection, powder, for solution Intravenous 1 g Injection, powder, for solution Parenteral 1 G Injection, powder, for suspension Intramuscular 250 MG/ML Powder, for solution 1.5 G Powder, for solution 2 G Powder, for solution 750 MG Injection, powder, for solution Intramuscular; Intravenous 1.5 g Injection, powder, for solution Intramuscular; Intravenous 750 mg Granule Oral 125 MG Injection, powder, lyophilized, for solution Intravenous Solution Parenteral 1500 mg Solution Parenteral 750.000 mg Injection Intramuscular; Intravenous Tablet, film coated Oral 500 mg Injection, powder, for solution Intramuscular 1 g Injection, powder, for solution Intramuscular 250 mg Injection, powder, for solution Intramuscular 500 mg Powder, for solution Intravenous 1.5 g / vial Powder, for solution Injection, powder, for solution 1 G Powder, for solution 1500 MG Injection, powder, for solution Intramuscular; Intravenous Solution Parenteral 750.00 mg Suspension Oral 1.250 g Tablet Oral 125 mg Granule, for suspension Oral 250 MG Injection Intramuscular; Intravenous 1.5 G Injection, solution Intravenous 1.5 mg Injection, solution Intravenous 250 mg Tablet Oral 500 MG Injection, powder, for solution Parenteral 1.5 g Injection, powder, for solution Intramuscular Injection, powder, for solution Intravenous Injection Intramuscular Injection, powder, for solution Intraocular Injection, powder, for solution Ophthalmic 50 MG Solution Intravenous 750.000 mg Powder, for suspension Oral Injection Intramuscular; Intravenous 1500 MG Injection Intramuscular; Intravenous 750 MG Injection, powder, for solution Intramuscular; Intravenous 750 mg/8.3mL Injection, powder, for solution Intramuscular; Intravenous 90 mg/1mL Injection, powder, for solution Intravenous 7.5 g/77mL Injection, powder, for solution Intravenous 750 mg/8.3mL Injection, powder, for solution Intravenous 90 mg/1mL Injection, powder, lyophilized, for solution Intravenous 1.5 g/1 Injection, powder, lyophilized, for solution Intravenous 750 mg/1 Injection, solution Intravenous 1.5 g/50mL Injection, solution Intravenous 750 mg/50mL Powder, for solution Intramuscular; Intravenous 1.5 g / vial Powder, for solution Intramuscular; Intravenous 750 mg / vial Powder, for solution Intravenous 7.5 g / vial Tablet Oral 250 mg Injection, solution Intramuscular; Intravenous 750 mg Granule, for suspension Oral 125 mg/5ml Granule, for suspension Oral 250 mg/5mL Granule Oral 5 g Powder Oral 250 mg/1vial Tablet, film coated Oral 250 mg Capsule Oral 500 mg Powder Oral 750 mg/1vial Tablet, film coated Oral 125 mg Capsule Oral 250 mg - Prices
Unit description Cost Unit Rocephin 10 gm vial 478.32USD vial Ceftin 20 500 mg tablet Bottle 436.36USD bottle Cefuroxime Axetil 250 mg/5ml Suspension 100ml Bottle 121.27USD bottle Rocephin 2 gm vial 97.5USD vial Cefzil 250 mg/5ml Suspension 100ml Bottle 87.62USD bottle Zinacef 7.5 gm vial 65.94USD vial Rocephin 1 gm Solution Vial 65.53USD vial Rocephin 1 gm vial 62.02USD vial Duricef 500 mg/5ml Suspension 100ml Bottle 59.36USD bottle Cefzil 125 mg/5ml Suspension 100ml Bottle 48.36USD bottle Duricef 500 mg/5ml Suspension 75ml Bottle 46.93USD bottle Maxipime 2 gram vial 43.04USD vial Velosef 250 mg/5ml Suspension 100ml Bottle 23.99USD bottle Maxipime 1 gm piggyback vial 23.24USD vial Duricef 250 mg/5ml Suspension 50ml Bottle 22.99USD bottle Maxipime 1 gram vial 21.7USD vial Ceftin 500 mg tablet 20.98USD tablet Cefuroxime 1.5 g/50 ml bag 16.8USD each Cedax 400 mg capsule 16.13USD each Zinacef 1.5 gm add-vant vial 13.94USD vial Zinacef 1.5 gm vial 13.45USD vial Cefuroxime sod 1.5 gm vial 13.44USD vial Ceftin 250 mg tablet 11.74USD tablet Cefzil 500 mg tablet 9.77USD tablet Cefuroxime axetil 500 mg tablet 8.11USD tablet Duricef 1 gm tablet 7.35USD tablet Cefzil 250 mg tablet 4.76USD tablet Ceftin 500 mg Tablet 3.61USD tablet Cefuroxime axetil 250 mg tablet 2.82USD tablet Velosef 500 mg capsule 2.02USD capsule Apo-Cefuroxime 500 mg Tablet 2.02USD tablet Ratio-Cefuroxime 500 mg Tablet 2.02USD tablet Ceftin 250 mg Tablet 1.82USD tablet Velosef 250 mg capsule 1.03USD capsule Apo-Cefuroxime 250 mg Tablet 1.02USD tablet Ratio-Cefuroxime 250 mg Tablet 1.02USD tablet Zinacef-water 1.5 gm/50 ml 0.32USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region CA2408198 No 2004-03-09 2022-11-21 Canada CA1328405 No 1994-04-12 2011-04-12 Canada
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 218-225 °C Not Available water solubility Freely soluble as sodium salt (145 mg/L) Not Available logP -0.16 SANGSTER (1993) - Predicted Properties
Property Value Source Water Solubility 0.284 mg/mL ALOGPS logP -0.24 ALOGPS logP -0.9 Chemaxon logS -3.2 ALOGPS pKa (Strongest Acidic) 2.96 Chemaxon pKa (Strongest Basic) -1.1 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 173.76 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 97.17 m3·mol-1 Chemaxon Polarizability 38.87 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.6504 Blood Brain Barrier - 0.9863 Caco-2 permeable - 0.7051 P-glycoprotein substrate Substrate 0.7253 P-glycoprotein inhibitor I Non-inhibitor 0.8621 P-glycoprotein inhibitor II Non-inhibitor 0.8383 Renal organic cation transporter Non-inhibitor 0.8688 CYP450 2C9 substrate Non-substrate 0.8686 CYP450 2D6 substrate Non-substrate 0.8196 CYP450 3A4 substrate Substrate 0.5051 CYP450 1A2 substrate Non-inhibitor 0.6957 CYP450 2C9 inhibitor Non-inhibitor 0.7771 CYP450 2D6 inhibitor Non-inhibitor 0.8707 CYP450 2C19 inhibitor Non-inhibitor 0.7064 CYP450 3A4 inhibitor Non-inhibitor 0.8308 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8916 Ames test Non AMES toxic 0.7525 Carcinogenicity Non-carcinogens 0.8816 Biodegradation Not ready biodegradable 0.9759 Rat acute toxicity 1.6593 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9724 hERG inhibition (predictor II) Non-inhibitor 0.8292
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-00dl-3926000000-2148cf05d31b3658ebcf Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-03dl-0039100000-260c620a855a9a196eb2 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-001i-9435000000-897e78cc7d827f5c45e5 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-040r-0396100000-1c9524e8025d4f7b9a47 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0f6y-3229000000-dc17f33419e16f6f0be4 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-9000000000-e5c2b52e879c01b9c4c8 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-008i-0419000000-87337a7a9023fa1c9d55 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 207.0744637 predictedDarkChem Lite v0.1.0 [M-H]- 211.52013 predictedDeepCCS 1.0 (2019) [M+H]+ 205.7838637 predictedDarkChem Lite v0.1.0 [M+H]+ 213.9157 predictedDeepCCS 1.0 (2019) [M+Na]+ 207.7075637 predictedDarkChem Lite v0.1.0 [M+Na]+ 219.85449 predictedDeepCCS 1.0 (2019)
Targets
- Kind
- Protein
- Organism
- Clostridium perfringens (strain 13 / Type A)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Transferase activity, transferring glycosyl groups
- Specific Function
- Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan str...
- Gene Name
- pbpA
- Uniprot ID
- Q8XJ01
- Uniprot Name
- Penicillin-binding protein 1A
- Molecular Weight
- 75176.35 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Cornaglia G, Ligozzi M, Bauernfeind A, Satta G, Fontana R: PBP binding and periplasmic concentration as determinants of the antibacterial activities of three new oral cephalosporins in Escherichia coli. New Microbiol. 1994 Jul;17(3):203-10. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Proton-dependent oligopeptide secondary active transmembrane transporter activity
- Specific Function
- Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
- Gene Name
- SLC15A1
- Uniprot ID
- P46059
- Uniprot Name
- Solute carrier family 15 member 1
- Molecular Weight
- 78805.265 Da
References
- Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Peptide:proton symporter activity
- Specific Function
- Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
- Gene Name
- SLC15A2
- Uniprot ID
- Q16348
- Uniprot Name
- Solute carrier family 15 member 2
- Molecular Weight
- 81782.77 Da
References
- Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [Article]
Drug created at June 13, 2005 13:24 / Updated at March 18, 2024 16:48